Literature DB >> 18594816

Planar and SPECT imaging in the era of PET and PET-CT: can it survive the test of time?

Abass Alavi1, Sandip Basu.   

Abstract

Mesh：

Year:  2008        PMID： 18594816     DOI： 10.1007/s00259-008-0813-2

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN： 1619-7070            Impact factor:   9.236


× No keyword cloud information.
  94 in total

1.  Complementary roles of PET and MR spectroscopy in the management of brain tumors.

Authors:  A Alavi; J B Alavi; R E Lenkinski
Journal:  Radiology       Date:  1990-12       Impact factor: 11.105

2.  11C-choline positron emission tomography in prostate cancer: primary staging and recurrent site staging.

Authors:  Soichiro Yoshida; Kazuaki Nakagomi; Shuichi Goto; Masami Futatsubashi; Tatsuo Torizuka
Journal:  Urol Int       Date:  2005       Impact factor: 2.089

3.  Ten years of experience with MIBG applications and the potential of new radiolabeled peptides: a personal overview and concluding remarks.

Authors:  B Shapiro
Journal:  Q J Nucl Med       Date:  1995-12

4.  Investigational study of iodine-124 with a positron camera.

Authors:  R M Lambrecht; N Woodhouse; R Phillips; D Wolczak; A Qureshi; E D Reyes; C Graser; S Al-Yanbawi; A Al-Rabiah; W Meyer
Journal:  Am J Physiol Imaging       Date:  1988

5.  Comparison of radiolabeled nucleoside probes (FIAU, FHBG, and FHPG) for PET imaging of HSV1-tk gene expression.

Authors:  Juri Gelovani Tjuvajev; Mikhail Doubrovin; Timothy Akhurst; Shangde Cai; Julius Balatoni; Mian M Alauddin; Ronald Finn; William Bornmann; Howard Thaler; Peter S Conti; Ronald G Blasberg
Journal:  J Nucl Med       Date:  2002-08       Impact factor: 10.057

Review 6.  Role of FDG-PET in the clinical management of paraneoplastic neurological syndrome: detection of the underlying malignancy and the brain PET-MRI correlates.

Authors:  Sandip Basu; Abass Alavi
Journal:  Mol Imaging Biol       Date:  2008-02-23       Impact factor: 3.488

Review 7.  Positron emission tomography in thyroid cancer management.

Authors:  Steven M Larson; Richard Robbins
Journal:  Semin Roentgenol       Date:  2002-04       Impact factor: 0.800

8.  Pre-therapeutic dosimetry and biodistribution of 86Y-DOTA-Phe1-Tyr3-octreotide versus 111In-pentetreotide in patients with advanced neuroendocrine tumours.

Authors:  Andreas Helisch; Gregor J Förster; Helmut Reber; Hans-Georg Buchholz; Rudolf Arnold; Burkhard Göke; Matthias M Weber; Bertram Wiedenmann; Stanislas Pauwels; Ulrike Haus; Hakim Bouterfa; Peter Bartenstein
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-06-03       Impact factor: 9.236

9.  Value of (124)I-PET/CT in staging of patients with differentiated thyroid cancer.

Authors:  L S Freudenberg; G Antoch; W Jentzen; R Pink; J Knust; R Görges; S P Müller; A Bockisch; J F Debatin; W Brandau
Journal:  Eur Radiol       Date:  2004-06-30       Impact factor: 5.315

10.  Glucose utilization by intracranial meningiomas as an index of tumor aggressivity and probability of recurrence: a PET study.

Authors:  G Di Chiro; J Hatazawa; D A Katz; H V Rizzoli; D J De Michele
Journal:  Radiology       Date:  1987-08       Impact factor: 11.105
View more
  12 in total

1.  Will high-resolution/high-sensitivity SPECT ensure that PET is not the only survivor in nuclear medicine during the next decade?

Authors:  Alain Seret
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-01-14       Impact factor: 9.236

2.  Re: Planar and SPECT imaging in the era of PET and PET-CT: can it survive the test of time?

Authors:  James R Ballinger
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-12       Impact factor: 9.236

3.  Is PET always an advantage versus planar and SPECT imaging?

Authors:  Giuliano Mariani; Laura Bruselli; Adriano Duatti
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-08       Impact factor: 9.236

4.  Positron emission and single-photon emission imaging: synergy rather than competition.

Authors:  Giuliano Mariani; H William Strauss
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-07       Impact factor: 9.236

Review 5.  A review on the clinical uses of SPECT/CT.

Authors:  Giuliano Mariani; Laura Bruselli; Torsten Kuwert; Edmund E Kim; Albert Flotats; Ora Israel; Maurizio Dondi; Naoyuki Watanabe
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-02-25       Impact factor: 9.236

Review 6.  Image-Guided Drug Delivery with Single-Photon Emission Computed Tomography: A Review of Literature.

Authors:  Rubel Chakravarty; Hao Hong; Weibo Cai
Journal:  Curr Drug Targets       Date:  2015       Impact factor: 3.465

7.  PET-based imaging to detect and characterize cardiovascular disorders: Unavoidable path for the foreseeable future.

Authors:  Abass Alavi; Thomas J Werner; Poul Flemming Høilund-Carlsen
Journal:  J Nucl Cardiol       Date:  2017-09-12       Impact factor: 5.952

Review 8.  Development of [(18)F]ASEM, a specific radiotracer for quantification of the α7-nAChR with positron-emission tomography.

Authors:  Andrew G Horti
Journal:  Biochem Pharmacol       Date:  2015-07-29       Impact factor: 5.858

Review 9.  Development of radioligands with optimized imaging properties for quantification of nicotinic acetylcholine receptors by positron emission tomography.

Authors:  Andrew G Horti; Yongjun Gao; Hiroto Kuwabara; Robert F Dannals
Journal:  Life Sci       Date:  2009-03-18       Impact factor: 5.037

10.  Noninvasive assessment of tumor VEGF receptors in response to treatment with pazopanib: a molecular imaging study.

Authors:  Francis G Blankenberg; Zoia Levashova; Susanta K Sarkar; John Pizzonia; Marina V Backer; Joseph M Backer
Journal:  Transl Oncol       Date:  2010-02       Impact factor: 4.243
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.